• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微生物群与肾小球肾炎:免疫学观点。

Microbiota and glomerulonephritis: An immunological point of view.

机构信息

Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Non-communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.

出版信息

Am J Med Sci. 2022 Dec;364(6):695-705. doi: 10.1016/j.amjms.2022.05.025. Epub 2022 Jul 20.

DOI:10.1016/j.amjms.2022.05.025
PMID:35870511
Abstract

Glomerular injury is the major cause of chronic kidney diseases (CKD) worldwide and is characterized by proteinuria. Glomerulonephritis (GN) has a wide spectrum of etiologies, the intensity of glomerular damage, histopathology, and clinical outcomes that can be associated with the landscape of the nephritogenic immune response. Beyond impaired immune responses and genetic factors, recent evidence indicates that microbiota can be contributed to the pathogenesis of GN and patients' outcomes by impacting many aspects of the innate and adaptive immune systems. It is still unknown whether dysbiosis induces GN or it is a secondary effect of the disease. Several factors such as drugs and nutritional problems can lead to dysbiosis in GN patients. It has been postulated that gut dysbiosis activates immune responses, promotes a state of systemic inflammation, and produces uremic toxins contributing to kidney tissue inflammation, apoptosis, and subsequent proteinuric nephropathy. In this review, the impact of gastrointestinal tract (GI) microbiota on the pathogenesis of the primary GN will be highlighted. The application of therapeutic interventions based on the manipulation of gut microbiota with special diets and probiotic supplementation can be effective in GN.

摘要

肾小球损伤是全球慢性肾脏病(CKD)的主要病因,其特征是蛋白尿。肾小球肾炎(GN)有广泛的病因、肾小球损伤的强度、组织病理学和临床结果,这些都与肾炎免疫反应的特征有关。除了受损的免疫反应和遗传因素外,最近的证据表明,微生物组通过影响先天和适应性免疫系统的许多方面,可能有助于 GN 的发病机制和患者的预后。目前尚不清楚是菌群失调导致了 GN,还是疾病的继发效应。一些因素,如药物和营养问题,可导致 GN 患者出现菌群失调。有人推测,肠道菌群失调会激活免疫反应,导致全身炎症状态,并产生尿毒症毒素,导致肾脏组织炎症、细胞凋亡和随后的蛋白尿性肾病。在这篇综述中,将强调胃肠道(GI)微生物群对原发性 GN 发病机制的影响。基于特殊饮食和益生菌补充剂来操纵肠道菌群的治疗干预措施的应用可能对 GN 有效。

相似文献

1
Microbiota and glomerulonephritis: An immunological point of view.微生物群与肾小球肾炎:免疫学观点。
Am J Med Sci. 2022 Dec;364(6):695-705. doi: 10.1016/j.amjms.2022.05.025. Epub 2022 Jul 20.
2
[Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].[慢性肾脏病肠道微生物群失调的发病机制、治疗及中药的干预作用]
Zhongguo Zhong Yao Za Zhi. 2017 Jul;42(13):2425-2432. doi: 10.19540/j.cnki.cjcmm.20170609.014.
3
The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus.肠道微生物群与慢性肾脏病的相互作用:炎症、蛋白尿、高血压和糖尿病的作用
Int Urol Nephrol. 2018 Aug;50(8):1453-1466. doi: 10.1007/s11255-018-1873-2. Epub 2018 May 4.
4
POTENTIAL THERAPEUTIC OPTIONS TARGETING THE GUT DYSBIOSIS IN CHRONIC KIDNEY DISEASE.靶向慢性肾脏病肠道菌群失调的潜在治疗选择。
Wiad Lek. 2022;75(7):1757-1764. doi: 10.36740/WLek202207127.
5
[Research Progress in the Correlation Between Oral Microbiota and Chronic Kidney Disease].[口腔微生物群与慢性肾脏病相关性的研究进展]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 Jan;54(1):66-70. doi: 10.12182/20230160202.
6
Gut Microbiota Alterations and Primary Glomerulonephritis in Children: A Review.肠道微生物组改变与儿童原发性肾小球肾炎:综述。
Int J Mol Sci. 2022 Dec 29;24(1):574. doi: 10.3390/ijms24010574.
7
Immunosenescence, gut dysbiosis, and chronic kidney disease: Interplay and implications for clinical management.免疫衰老、肠道菌群失调与慢性肾脏病:相互作用及对临床管理的影响。
Biomed J. 2024 Apr;47(2):100638. doi: 10.1016/j.bj.2023.100638. Epub 2023 Jul 29.
8
Impact of gut microbiota: How it could play roles beyond the digestive system on development of cardiovascular and renal diseases.肠道微生物组的影响:它如何超越消化系统在心血管和肾脏疾病发展中发挥作用。
Microb Pathog. 2021 Mar;152:104583. doi: 10.1016/j.micpath.2020.104583. Epub 2020 Oct 24.
9
Intestinal Microbiota in Type 2 Diabetes and Chronic Kidney Disease.2型糖尿病和慢性肾脏病中的肠道微生物群
Curr Diab Rep. 2017 Mar;17(3):16. doi: 10.1007/s11892-017-0841-z.
10
The Impact of CKD on Uremic Toxins and Gut Microbiota.慢性肾脏病对尿毒症毒素和肠道微生物群的影响。
Toxins (Basel). 2021 Mar 31;13(4):252. doi: 10.3390/toxins13040252.

引用本文的文献

1
The Risk Factors of Hypotension in Patients with End-Stage Chronic Glomerulonephritis During Maintenance Hemodialysis.终末期慢性肾小球肾炎患者维持性血液透析期间低血压的危险因素
Int J Gen Med. 2025 Aug 28;18:4885-4892. doi: 10.2147/IJGM.S536545. eCollection 2025.
2
Role of metabolomic profile as a potential marker to discriminate membranous nephropathy from IgA nephropathy.代谢组学特征作为鉴别膜性肾病和 IgA 肾病的潜在标志物的作用。
Int Urol Nephrol. 2024 Feb;56(2):635-651. doi: 10.1007/s11255-023-03691-1. Epub 2023 Jul 15.
3
The effect of gut microbiota dysbiosis on patients with preeclampsia.
肠道微生物菌群失调对先兆子痫患者的影响。
Front Cell Infect Microbiol. 2023 Jan 4;12:1022857. doi: 10.3389/fcimb.2022.1022857. eCollection 2022.